Navigation Links
University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
Date:1/31/2011

rvival is around 3-5 years. Chronic myeloid leukemia can occur at any age, but it more commonly affects middle-aged and older people.

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

About the University of SouthamptonThe University of Southampton is a leading UK teaching and research institution with a global reputation for leading-edge research and scholarship across a wide range of subjects in engineering, science, social sciences, health and humanities.

With over 22,000 students, around 5000 staff, and an annual turnover well in excess of 400 million pounds Sterling, the University of Southampton is acknowledged as one of the country's top institutions for engineering, computer science and medicine. We combine academic excellence with an innovative and entrepreneurial approach to research, supporting a culture that engages and challenges students and staff in their pursuit of learning.

The University is also home to a number
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
2. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
4. Stereotaxis Announces Global Initial Training Site at University of Chicago
5. SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System
6. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
7. The University of Tennessee Medical Center and ContinuumRx Form Healthcare Joint Venture
8. D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center
9. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
10. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
11. Siemens Wins $25 Million Contract From Rush University Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The Assistance Fund announces the addition of ... assistance for copay to individuals diagnosed with Melanoma. ... of the Melanoma Copay Assistance Program to our portfolio ... director. "With each additional program we are closer to ... no one is denied access to medications due to ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... Corporation (Nasdaq: DNDN ) today announced that ... Phase 1 clinical trial of D3263 in patients with ... drug candidate designed to target TRPM8 (a transmembrane cation ... The trial is an open-label, dose-escalation study evaluating ...
... strategies for personalized approach to cancer treatmentSEATTLE, April ... subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and ... which utilized RNA interference (RNAi) and bioinformatics to ... that enhance the anti-tumor response to the experimental ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:5/25/2015)... World Patent Marketing, a vertically integrated ... Little Party Table, a party invention that gives people ... suit their party needs. , "Worldwide indoor and outdoor ... past year. Party Supply Rentals alone are a ... CEO and Creative Director of World Patent Marketing ...
(Date:5/25/2015)... Iowa City, Iowa (PRWEB) May 25, 2015 ... Engineering Excellence awards for design of the ... in Iowa City, Iowa.    The project received a National Recognition ... and an Honor Award from ACEC – Iowa. ... outstanding engineering achievements. , The $50.2 million expansion is ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... patients for concerns about hair loss. Although it is ... clear that there are environmental factors such as metabolism, ... can contribute. Since they offer a comprehensive approach to ... peri and post-menopausal woman, they can help patients find ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... health insurance providers can motivate and sustain member participation in wellness ... ... Louis, MO (PRWEB) November 6, 2008 -- As a strategic partner ... new whitepaper for health insurance companies that need to improve wellness ...
... Long-Lasting Results and Physician Expertise Most Important, ... A new study,conducted by the American Society ... business of sanofi-aventis U.S. LLC, reveals the,influencers ... medical,anti-aging treatments. The study surveyed women ages ...
... 6 Continuing its efforts to,educate, inform, and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, November 10, 2008 at 6:00 PM on ... frank discussion with Joy Loverde, a,nationally known expert ...
... and Healthier for People With,Diabetes and Their Caregivers, ... a time,for love, laughter, and family, usually accompanied by ... temptations may leave some,of the nearly 24 million people ... Last holiday season, dLife helped over 100,000 online,visitors survive ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,090,000 compared to total ... 2008 ended September 30, 2007. Total revenue was comprised,of ... of Protein A revenue, for the second quarter of ...
... Corporation,(Nasdaq: RGEN ) announced today that the ... evaluate the use of RG2417, an oral formulation ... 2b study is a,multi-center, randomized, double-blind, placebo-controlled clinical ... will receive,either RG2417 or placebo twice daily for ...
Cached Medicine News:Health News:Health and Wellness Incentives 2Health News:New Study Reveals What Women Want When Considering Cosmetic Procedures 2Health News:Health Caring for the Elderly 2Health News:Back By Popular Demand - dLife Holiday Helpline 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 7Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 8Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
... only task-critical information to the operator ... Up to 14 additional computers can ... the facility using a dedicated local ... and administrators can all access the ...
... VerdaSee Patient Bracelet-ID™ provides a solution ... personnel to elopement or unauthorized movement ... issues are a key concern. Certain ... care, Alzheimer's victims, patients with highly ...
... a small radio transmitter combines state-of-the-art ... design. The tag incorporates a tamper ... as the tag is attached to ... electronic Heartbeat® signal every 10 seconds ...
Medicine Products: